As one of Bird & Bird's most experienced intellectual property partners, specialising in transactional IP matters, I offer a wealth of knowledge to businesses at the cutting edge of research, development and technology, in a variety of sectors for which IP is of prime importance.

Providing the full array of commercial advice and support in IP, I lead the team delivering licensing, partnering and exploitation agreements, and research, development and marketing collaborations. I also advise our clients on regulatory and 'freedom to operate' issues, and manage significant due diligence matters.

As a transactional IP lawyer, I provide advice on the protection and exploitation of IP rights, both in stand-alone transactions and as part of acquisition, divestment or investment activity.

Before joining Bird & Bird in 2006, I was head of IP &Life Sciences at another global law firm, after spending 11 years in-house firstly as senior legal adviser at ICI/Zeneca and latterly as Legal Director of Novartis UK. This experience has given me significant insight into the need for pragmatic commercial advice.

As well as speaking on IP generally, and regulatory life sciences topics particularly, I contribute to leading publications, and I edit The Guide to EU Pharmaceutical Regulatory Law (Kluwer Law International), which is written entirely by the team at Bird & Bird with contributions from many offices. I also lead the Bird & Bird Brexit Steering Committee and write and speak on the implications of Brexit, particularly in relation to the life sciences and medical devices industries.

  • Chiesi Pharmaceuticals: advising on the European aspects of an international acquisition from Horizon Pharma plc of the European marketing rights to two cystic fibrosis products.
  • Cheminova: acting on the asset sale of 4 active ingredients in the EEA.
  • FMC Crop Science: advising in relation to its divestment to Nufarm Limited of a portion of its European herbicide portfolio.
  • Chiesi Farmaceutici S.p.A: advising in relation to its acquisition from Dublin-based Horizon Pharma of the rights to PROCYSBI (cysteamine bitartrate) and QUINSAIR (levofloxacin inhalation solution) in the EMEA regions for. Horizon's facilities in the Netherlands, France and Germany and its 40 employees were included in the deal.
  • Royal Marsden NHS Foundation Trust: providing general IP, licensing and commercial advice to this leading cancer research hospital.
  • I represented a significant UK based pharmaceutical company in one of the first PRAC cases at EMA.
  • University of Manchester, LLB Hons, Law
  • College of Law, Lancaster Gate - Law Society Finals
  • Law Society of England & Wales in 1988
  • Law Society of Ireland in 2017


25 September 2019

Our Brexit resources include over 30 practice group and sector briefings, practical tools for businesses and various videos.

Read More